Literature DB >> 10228079

Longitudinal quantification of human immunodeficiency virus type 1 DNA and RNA in long-term nonprogressors.

C Broström1, U Visco-Comandini, Z Yun, A Sönnerborg.   

Abstract

Twenty patients with human immunodeficiency virus type 1 (HIV-1) infection for >7 years, no HIV-1-related symptoms, no treatment, and CD4+ cell counts >500/microL were included in a prospective study in 1993. Four years later, 12 patients had progressed (SPs), while 8 had not (long-term nonprogressors [LTNPs]). At inclusion, HIV-1 RNA, but not DNA, levels were higher in SPs. During follow-up, a consistent increase in HIV-1 RNA was seen in only 1 LTNP. In 2 LTNPs, plasma viremia was persistently undetectable or <110 copies/mL. Infectious virus was isolated from only 1 LTNP and from 11 SPs. In 4 LTNPs, HIV-1 DNA levels decreased spontaneously with time. The restricted viral replication and the declining HIV-1 DNA levels suggest that the HIV-1 infection can be controlled efficiently in a few LTNPs, leading to a decrease in the total virus burden with time.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10228079     DOI: 10.1086/314757

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  5 in total

1.  Quantification of human immunodeficiency virus type 1 proviral DNA by the TaqMan real-time PCR assay.

Authors:  Zhibing Yun; Eva Fredriksson; Anders Sönnerborg
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

2.  Immunization of cats against feline immunodeficiency virus (FIV) infection by using minimalistic immunogenic defined gene expression vector vaccines expressing FIV gp140 alone or with feline interleukin-12 (IL-12), IL-16, or a CpG motif.

Authors:  C M Leutenegger; F S Boretti; C N Mislin; J N Flynn; M Schroff; A Habel; C Junghans; S A Koenig-Merediz; B Sigrist; A Aubert; N C Pedersen; B Wittig; H Lutz
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  Genetic characterization of human immunodeficiency virus type 1 in elite controllers: lack of gross genetic defects or common amino acid changes.

Authors:  Toshiyuki Miura; Mark A Brockman; Chanson J Brumme; Zabrina L Brumme; Jonathan M Carlson; Florencia Pereyra; Alicja Trocha; Marylyn M Addo; Brian L Block; Alissa C Rothchild; Brett M Baker; Theresa Flynn; Arne Schneidewind; Bin Li; Yaoyu E Wang; David Heckerman; Todd M Allen; Bruce D Walker
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

4.  Persistence of extraordinarily low levels of genetically homogeneous human immunodeficiency virus type 1 in exposed seronegative individuals.

Authors:  Tuofu Zhu; Lawrence Corey; Yon Hwangbo; Jean M Lee; Gerald H Learn; James I Mullins; M Juliana McElrath
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

5.  Different patterns of HIV-1 DNA after therapy discontinuation.

Authors:  Maria Carla Re; Francesca Vitone; Laura Sighinolfi; Pasqua Schiavone; Florio Ghinelli; Davide Gibellini
Journal:  BMC Infect Dis       Date:  2005-09-12       Impact factor: 3.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.